Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial. (2020)
Attributed to:
R Phillips, KNUST Ghana. Pathogenesis and management of M. ulcerans disease, Buruli ulcer
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/s0140-6736(20)30047-7
PubMed Identifier: 32171422
Publication URI: http://europepmc.org/abstract/MED/32171422
Type: Journal Article/Review
Volume: 395
Parent Publication: Lancet (London, England)
Issue: 10232
ISSN: 0140-6736